Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agiliti, Inc. stock logo
AGTI
Agiliti
$10.05
-0.5%
$10.06
$5.07
$18.61
$1.37B1.91.78 million shs26.51 million shs
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$6.84
-1.0%
$6.69
$3.33
$7.62
$1.32B1.321.90 million shs306,722 shs
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$25.66
+1.3%
$27.87
$9.44
$36.25
$1.33B2.94928,398 shs115,410 shs
Omnicell, Inc. stock logo
OMCL
Omnicell
$30.95
+1.7%
$28.37
$25.69
$77.14
$1.42B0.77531,301 shs110,457 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agiliti, Inc. stock logo
AGTI
Agiliti
0.00%0.00%+0.15%+26.73%-39.64%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
0.00%-2.12%+6.47%+11.99%+87.77%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
0.00%-1.40%+0.36%-7.04%+40.39%
Omnicell, Inc. stock logo
OMCL
Omnicell
0.00%+1.06%+9.38%+6.51%-58.51%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agiliti, Inc. stock logo
AGTI
Agiliti
1.7594 of 5 stars
2.94.00.00.00.02.50.0
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.4271 of 5 stars
1.32.00.04.92.21.70.6
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.8415 of 5 stars
4.51.00.00.03.12.50.0
Omnicell, Inc. stock logo
OMCL
Omnicell
2.5801 of 5 stars
3.21.00.00.03.41.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agiliti, Inc. stock logo
AGTI
Agiliti
1.86
Reduce$14.1740.96% Upside
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.50
Moderate Buy$7.509.65% Upside
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
3.00
Buy$44.2272.34% Upside
Omnicell, Inc. stock logo
OMCL
Omnicell
2.33
Hold$42.2036.35% Upside

Current Analyst Ratings

Latest BKD, OMCL, FDMT, and AGTI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
4/30/2024
Omnicell, Inc. stock logo
OMCL
Omnicell
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00
4/15/2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$35.00 ➝ $40.00
4/15/2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
4/9/2024
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$9.00
4/1/2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$70.00 ➝ $63.00
4/1/2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $58.00
3/26/2024
Agiliti, Inc. stock logo
AGTI
Agiliti
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
3/7/2024
Agiliti, Inc. stock logo
AGTI
Agiliti
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$10.00
3/1/2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
(Data available from 5/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agiliti, Inc. stock logo
AGTI
Agiliti
$1.17B1.16$1.74 per share5.76$6.98 per share1.44
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$3.02B0.44$0.84 per share8.10$2.15 per share3.18
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$20.72M64.03N/AN/A$7.20 per share3.56
Omnicell, Inc. stock logo
OMCL
Omnicell
$1.15B1.24$3.20 per share9.68$26.15 per share1.18

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agiliti, Inc. stock logo
AGTI
Agiliti
-$19.42M-$0.14N/A21.38N/A-1.65%6.47%2.53%N/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$189.01M-$0.77N/AN/AN/A-5.71%-44.72%-3.55%8/5/2024 (Estimated)
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$100.84M-$2.44N/AN/AN/A-436.30%-26.75%-24.84%8/14/2024 (Estimated)
Omnicell, Inc. stock logo
OMCL
Omnicell
-$20.37M-$0.46N/A88.43137.80-1.91%2.41%1.28%8/6/2024 (Estimated)

Latest BKD, OMCL, FDMT, and AGTI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2024N/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.73-$0.66+$0.07-$0.66$1.44 million$0.03 million
3/5/2024Q4 2023
Agiliti, Inc. stock logo
AGTI
Agiliti
$0.10$0.11+$0.01$0.26$291.99 million$291.99 million
2/29/2024Q4 2023
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.68-$0.77-$0.09-$0.77$4.67 million($0.02) million
2/20/2024Q4 2023
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$0.19-$0.40-$0.21-$0.40N/A$754.48 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agiliti, Inc. stock logo
AGTI
Agiliti
N/AN/AN/AN/AN/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
N/AN/AN/AN/AN/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
Omnicell, Inc. stock logo
OMCL
Omnicell
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agiliti, Inc. stock logo
AGTI
Agiliti
1.13
1.72
1.34
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
10.23
0.84
0.84
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/A
32.65
32.65
Omnicell, Inc. stock logo
OMCL
Omnicell
0.48
2.38
2.13

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Agiliti, Inc. stock logo
AGTI
Agiliti
99.12%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
N/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
99.27%
Omnicell, Inc. stock logo
OMCL
Omnicell
97.70%

Insider Ownership

CompanyInsider Ownership
Agiliti, Inc. stock logo
AGTI
Agiliti
4.16%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
1.50%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
7.30%
Omnicell, Inc. stock logo
OMCL
Omnicell
2.64%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Agiliti, Inc. stock logo
AGTI
Agiliti
5,800136.08 million130.42 millionOptionable
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
25,200193.01 million190.12 millionOptionable
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
14751.70 million47.93 millionOptionable
Omnicell, Inc. stock logo
OMCL
Omnicell
3,65045.92 million44.71 millionOptionable

BKD, OMCL, FDMT, and AGTI Headlines

Recent News About These Companies

Omnicell (NASDAQ:OMCL) Stock Price Down 4.7%
Omnicell (NASDAQ:OMCL) Trading Up 4.8%
Piper Sandler Keeps Their Buy Rating on Omnicell (OMCL)
LeMaitre Vascular declares $0.16 dividend
Q1 2024 Omnicell Inc Earnings Call
Omnicell: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Agiliti logo

Agiliti

NYSE:AGTI
Agiliti, Inc., together with its subsidiaries, provides healthcare technology management and service solutions to the healthcare industry in the United States. The company offers onsite managed services that are comprehensive programs for the management, reprocessing, and logistics of medical equipment at individual facilities and integrated delivery networks to monitor and adjust equipment quantities and availability to address fluctuations in patient census and acuity. It also provides clinical engineering services comprising maintenance, repair, and remediation solutions for various types of medical equipment, including general biomedical equipment, diagnostic imaging equipment, and surgical equipment through supplemental and outsourced offerings. In addition, the company offers equipment solutions, which primarily provide supplemental, peak need, and per-case rental of general biomedical, specialty, and surgical equipment to acute care hospitals and alternate site providers, including premier healthcare institutions and integrated delivery networks. It serves acute care hospitals, health systems and integrated delivery networks and alternate site providers. The company was founded in 1939 and is headquartered in Eden Prairie, Minnesota. Agiliti, Inc. operates as a subsidiary of THL Agiliti LLC.
Brookdale Senior Living logo

Brookdale Senior Living

NYSE:BKD
Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.
4D Molecular Therapeutics logo

4D Molecular Therapeutics

NASDAQ:FDMT
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Omnicell logo

Omnicell

NASDAQ:OMCL
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.